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Left ventricular hypertrophy (LVH), the major manifestation of hypertensive heart disease (HHD), is a strong, indepen-
dent risk factor for cardiovascular morbidity and mortality.1 
Although LVH has been attributed to many causes, such as 
hemodynamic and humoral factors, inflammation may exert a 
detrimental effect on myocardial structure favoring the devel-
opment of LVH.2 However, the underlying mechanisms are not 
well understood. Such inflammatory processes include elevated 
levels of cytokines (such as interleukin-6 [IL-6])3 and increased 
reactive oxygen species generation by circulating cells.4
Oxidative stress associates with arterial hypertension and con-
stitutes a potential mechanism that promotes LVH.5,6 A major 
source of superoxide anion in the cardiovascular system is the 
NADPH oxidase family, present in endothelial cells, smooth mus-
cle cells, fibroblasts, cardiomyocytes, and phagocytes, includ-
ing monocytes/macrophages.7 The phagocytic NADPH oxidase 
consists of 2 membrane-bound subunits (Nox2 and p22phox) 
and cytosolic subunits (p47phox, p67phox, p40phox, and rac2), 
which on stimulation are phosphorylated and translocate to 
membrane to form the catalytically active oxidase.8 Numerous 
evidences associate the activation of the NADPH oxidases with 
the pathophysiology of cardiovascular diseases, including human 
hypertension.5,7,9,10 Humoral factors such as angiotensin II,9 endo-
thelin-1,9 and insulin11 may activate the phagocytic NADPH oxi-
dase. Experimental studies support the implication of circulating 
monocytes and lymphocytes in angiotensin II–induced hyper-
tension, in part attributable to an NADPH oxidase–dependent 
mechanism.12 Among other effects, the NADPH oxidase overac-
tivation results in increased IL-6 secretion in human monocytes.13 
The NADPH oxidase also responds to cytokine stimulation.14
Cardiotrophin-1 (CT-1) is a member of the IL-6 superfam-
ily of cytokines that signals via LIF (leukemia inhibitory fac-
tor) receptor-gp130–dependent pathways.15 Although originally 
characterized as a survival factor,16 chronically elevated CT-1 
may contribute to left ventricular (LV) growth and dysfunction 
in hypertension. Plasma levels of CT-1 are elevated in hyper-
tensive patients, namely in those with LVH.17 Regression of 
LVH and reduction of plasma levels of CT-1 associate in treated 
hypertensive patients.17 Finally, CT-1 is increased in the myo-
cardium and plasma of hypertensive patients with heart failure.18
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To analyze whether the systemic superoxide generation 
participates in LVH in hypertensive patients and that CT-1 
may be relevantly involved, we analyzed the relationship of 
the NADPH oxidase–dependent superoxide production by 
peripheral blood mononuclear cells (PBMCs) with the LVH 
in a cross-sectional study. Besides, we explored the role of 
CT-1 as an inducer of the NADPH oxidase in PBMCs and the 
subsequent proinflammatory phenotype.
Methods
Additional Methods are available in the online-only Data Supplement.
Subjects
According to institutional guidelines, subjects were aware of the 
research nature of the study and agreed to participate. The study was 
performed in accordance with the Declaration of Helsinki, and the 
Ethical Committee of the University Clinic of Navarra approved the 
protocol.
The study was performed in 140 unrelated white subjects who vol-
untarily came to our institution for a routine medical work-up after a 
12-hour overnight fast. Blood pressure was measured on 3 occasions 
using a mercury sphygmomanometer, and the mean was recorded. 
Subjects were considered hypertensives (n=122) if they presented 
systolic blood pressure (SBP) and diastolic blood pressure of more 
than 139 and 89 mm Hg, respectively, or were under antihypertensive 
treatment. Patients had appropriate clinical, laboratory, and radiologi-
cal evaluations to exclude secondary hypertension and chronic kidney 
disease. Normotensive subjects (n=18) presented repeated measure-
ments of SBP and diastolic blood pressure below 140 and 90 mm Hg, 
respectively. The presence of LVH as determined by echocardiography 
was established when LV mass index (LVMI) was >111 g/m2 for men 
and >106 g/m2 for women.19 Of the 122 hypertensives, 80 presented 
LVH. None of the hypertensive patients presented echocardiographic 
evidence of aortic stenosis or hypertrophic cardiomyopathy or clinical 
manifestations of heart failure. Thirty healthy volunteers were also re-
cruited, and a sample of venous blood was obtained for in vitro studies.
Statistical Analysis
Quantitative variables are expressed as mean±SEM or interquartile 
range with 95% confidence interval and categorical variables as num-
bers and percentages. To compare categorical variables, the χ2 test 
was used. To compare numeric variables between patient groups, a 
1-way ANOVA followed by a Student-Newman-Keuls test was per-
formed once normality was checked (Shapiro–Wilk test); otherwise, 
the nonparametric Kruskal–Wallis test followed by a Mann–Whitney 
U test (adjusting the α-level by Bonferroni inequality) was used. The 
association between variables was tested calculating Pearson corre-
lation coefficient or Spearman correlation coefficient. Adjustments 
for confounding factors were performed in linear regression tests. 
Significance was defined as 2-sided P<0.05. The analyses were per-
formed with SPSS 15.0.
Results
Clinical and Echocardiographic Characteristics
The Table shows the clinical and echocardiographic character-
istics of the subjects. Age, body mass index (BMI), and blood 
pressure values were significantly higher in the 2 groups of 
hypertensive patients as compared with normotensive sub-
jects, whereas no differences existed for these parameters 
between hypertensives with LVH and hypertensives without 
LVH. No differences were found between hypertensives with 
LVH and hypertensives without LVH in the antihypertensive 
medication or in statin treatment. Among echocardiographic 
parameters, LV end-diastolic diameter, LVMI, left atrial 
anteroposterior diameter, and relative wall thickness were 
significantly higher in hypertensives with LVH as compared 
with normotensives, whereas the ratio of the early and late 





nificantly lower in hypertensives with LVH as compared with 
normotensives. LV end-diastolic diameter, LVMI, left atrial 
anteroposterior diameter, and relative wall thickness were sig-
nificantly higher in hypertensives with LVH as compared with 
hypertensives without LVH. No other differences among the 3 
groups were observed in the remaining parameters.
NADPH Oxidase–Dependent Superoxide Anion 
Production in PBMCs
The superoxide anion production by PBMCs in response to phor-
bol myristate acetate (PMA) was increased in hypertensives with 
LVH compared with hypertensives without LVH and normoten-
sive individuals (Figure 1). It was also higher in hypertensives 
without LVH than in normotensives. The chemiluminescence 
results were corroborated by measuring superoxide with the 
superoxide dismutase–inhibitable ferricytochrome c reduction 
(online-only Data Supplement and Figure S1 in the online-only 
Data Supplement). The chemiluminescent signal was inhibited 
by superoxide dismutase, thus indicating that lucigenin detected 
superoxide (Figure S2). The PMA-stimulated superoxide anion 
production was inhibited by diphenylene iodonium, gp91ds-tat, 
and apocynin (Figure S2). Oxypurinol, rotenone, and L-NAME 
(L-NG-nitro-arginine methyl esther) did not inhibit superoxide 
production. Moreover, bisindolyl maleimide and wortman-
nin blunted PMA-induced superoxide production (Figure S2). 
Finally, PMA promoted the translocation of p47phox subunit from 
the cytosol to membranes, a direct index of NADPH oxidase 
activation in PBMCs (Figure S2). Collectively, these results sub-
stantiate the notion that NADPH oxidase is the major source of 
superoxide in PBMCs in response to PMA.11
Association of the NADPH Oxidase–Dependent 
Superoxide Anion Generation With 
Echocardiographic Parameters
The superoxide anion production by PBMCs correlated directly 
with the LVMI after adjusting for age, sex, BMI, and SBP 
(Figure 2A). A multivariate analysis adjusting for age, sex, 
BMI, and SBP indicates that an increase in 1 U (relative light 
units/s) of superoxide production resulted in an increase in 0.458 
U of LVMI (P=0.033). The superoxide production correlated 
inversely with the deceleration time (Figure 2B) and directly 
with the left atrial anteroposterior diameter (Figure 2C). The 
correlations with the deceleration time (r=−0.323; P=0.005) and 
the left atrial anteroposterior diameter (r=0.259; P=0.023) were 
maintained in the hypertensives with LVH (HT+LVH) group.
Serum Concentration of Cytokines
CT-1 levels were increased in hypertensive patients with LVH 
compared with normotensive subjects and hypertensive patients 
without LVH (Figure 3A). Serum CT-1 levels were also higher 
in hypertensives without LVH than in normotensives, although 
the difference did not reach statistical significance. Moreover, 
serum CT-1 levels correlated directly with the superoxide pro-
duction by PBMCs after adjusting for age, sex, SBP, and BMI 
(Figure 3B). This correlation was also evident when only the 
HT+LVH group was analyzed (r=0.478; P<0.001).
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Taking into account that activated monocytes release IL-6,4 
we investigated circulating IL-6 levels in our population. 
They were increased in hypertensives with LVH compared 
with normotensives and hypertensives without LVH and also 
higher in hypertensives without LVH than in normotensives 
(Figure S3). Serum IL-6 levels correlated with the superoxide 
production after adjusting for age, sex, SBP, and BMI (Figure 
S3). This correlation was also evident when only the HT+LVH 
group was analyzed (r=309; P=0.007).
Serum CT-1 levels correlated with serum IL-6 lev-
els (r=0.217; P=0.015). Moreover, serum CT-1 (r=0.335; 
P<0.001) and IL-6 (r=0.231; P=0.021) levels correlated 
directly with the LVMI. CT-1 levels correlated with the LVMI 
after adjusting for age, sex, SBP, BMI, superoxide production, 
and IL-6 levels (r=0.286; P<0.001).
In Vitro Studies on PBMCs
To evaluate the cause–effect relationship behind the correla-
tion of circulating CT-1 levels and NADPH oxidase–depen-
dent superoxide generation, we incubated human PBMCs 
isolated from 30 healthy individuals with recombinant human 
CT-1 for 10 minutes, detecting an increased superoxide pro-
duction in a dose-dependent manner (Figure S4). This super-
oxide production was inhibited by diphenylene iodonium, 
gp91ds-tat, and apocynin (Figure 4A). Oxypurinol, rote-
none, and L-NAME did not inhibit the superoxide generation 




Age, y 50±2 56±1 59±1
P=0.028* P=0.001*
P=0.035†
Sex, male/female 14/4 33/9 65/15
Body mass index, kg/m2 27.7±0.8 29.7±0.7 29.8±0.5
P=0.037* P=0.043*
Systolic blood pressure, mm Hg 119±3 139±2 140±2
P<0.001* P<0.001*
Diastolic blood pressure, mm Hg 79±1 86±1 86±1
P<0.001* P<0.001*
Pulse pressure, mm Hg 40±4 52±2 53±1
P<0.001* P<0.001*
Medication, n (%) 0 26 (62) 54 (67)
  Angiotensin converting enzyme inhibitors 0 9 (21) 12 (15)
  Angiotensin receptor antagonists 0 10 (24) 15 (19)
  Other antihypertensives 0 15 (36) 35 (43)
  Statins 2 (11) 8 (19) 13 (16)
Left ventricular end-diastolic diameter, mm 45.5±1.3 46.3±0.8 52.8±0.6
P<0.001*
P<0.001†
Left ventricular mass index, g/m2 81.0±3.7 83.8±2.8 142.8±2.8
P<0.001*
P<0.001†
Relative wall thickness 0.40±0.02 0.41±0.01 0.45±0.01
P=0.013*
P<0.028†
Left ventricular ejection fraction, % 65.6±2.1 63.0±1.0 63.2±0.9
Left atrial anteroposterior diameter, mm 35.9±2.1 36.8±1.1 39.4±0.7
P=0.031*
P=0.042†
Deceleration time, ms 219±12 222±8 228±6
VE/VA 1.03±0.05 0.92±0.05 0.86±0.03
P=0.035*
LVH indicates left ventricular hypertrophy; V
A
, late maximum transmitral velocity in diastole; and V
E
, early maximum transmitral 
velocity in diastole.
*P value vs normotensives.
†P value vs hypertensives without LVH.
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(Figure 4A). Moreover, CT-1 promoted the translocation of 
p47phox subunit from the cytosol to membranes in PBMCs 
(Figure 4B). Collectively, these results support that CT-1 acti-
vates the phagocytic NADPH oxidase. CT-1–induced super-
oxide generation was blunted when PKC (protein kinase C) 
or PI3K (phosphatidylinositide 3-kinase) were inhibited or 
when gp130/LIF receptor was blocked (Figure 4C). Inhibition 
of MEK1/2 (MAP kinase kinase 1/2) did not affect the CT-1–
induced superoxide generation (Figure 4C).
Stimulation of PBMCs with CT-1 significantly increased 
IL-6 secretion, which was inhibited in the presence of apocy-
nin (Figure S5), suggesting that the CT-1–dependent release 
of IL-6 is mediated by the NADPH oxidase. Interestingly, 
24-hour incubation with CT-1 upregulated Nox2 (Figure S6).
CT-1 also increased superoxide production in human 
umbilical vein endothelial cells (Figure S7). Interestingly, 
IL-6 induced superoxide production in PBMCs, an effect that 
was inhibited by gp91ds-tat (Figure S8).
Discussion
The main finding of this study is that the NADPH oxidase–
dependent superoxide anion production is enhanced in 
PBMCs from hypertensive patients with LVH as compared 
with cells from both hypertensives without LVH and normo-
tensives. The NADPH oxidase–dependent superoxide anion 
production correlates with LV mass and function, as well as 
with left atrial morphology. Moreover, our results show that 
CT-1 can contribute to systemic oxidative stress by activating 
the NADPH oxidase in PBMCs and that, as a consequence, 
a further proinflammatory and prohypertrophic profile (IL-6 
secretion) is induced. Taken together, our results support the 
notion that the PBMC NADPH oxidase overactivity may play 
a major role in LVH in hypertensive patients (Figure S9).
White cell numbers are increased in patients with hyper-
tension and may be a marker of events.20 White cells present 
a primed phenotype: they are more prone to release reactive 
Figure 2. Correlation of superoxide production by peripheral 
blood mononuclear cells with (A) the left ventricular mass 
index (LVMI), (B) the deceleration time, and (C) the left atrial 
anteroposterior diameter (LAAPD) after adjusting for age, sex, 
body mass index, and systolic blood pressure.
Figure 1. Superoxide production by peripheral blood mono­
nuclear cells from normotensives (NT, n=18; 10.7±1.6 relative light 
units [RLU]/s [95% confidence interval {CI}, 7.6 to 14.3 RLU/s]), 
hypertensives without left ventricular hypertrophy (HT−LVH, n=42; 
14.1±1.1 RLU/s [95% CI, 11.8 to 16.3 RLU/s]), and hypertensives 
with LVH (HT+LVH, n=80; 21.9±1.8 RLU/s [95% CI, 18.4 to 25.5 
RLU/s]). *P=0.046 vs NT (CI, −7.59 to −0.03); †P=0.011 vs NT 
(CI, −18.62 to −3.36); #P=0.028 vs HT−LVH (CI, −13.00 to −2.73).
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oxygen species,4,21 their gene expression is altered,22 and dis-
play a proadhesive phenotype.21 Target organs such as the heart 
display higher levels of proinflammatory molecules,23 which 
promote white cell infiltration.24 Such activated, infiltrated 
white cells turn into local sources of oxidative stress, proin-
flammatory cytokines, and matrix metalloproteinases,25,26 thus 
contributing to myocardial remodeling. Monocytes and lym-
phocytes may play a relevant role in the genesis of angioten-
sin II–induced hypertension, in part attributable to NADPH 
oxidase–dependent mechanisms, therefore supporting the role 
of inflammation in the basis of hypertension.12
The NADPH oxidase system is a multimeric enzyme that 
was first described in phagocytes as a source of superoxide 
anion with bactericidal properties; thereafter, diverse variants 
of the enzyme have been described throughout the organ-
ism, with varied and relevant pathophysiological roles.8 Local 
NADPH oxidases play a role in the development and outcome 
of cardiovascular diseases.7 Likewise, the NADPH oxidase of 
circulating cells may be influenced by the systemic proinflam-
matory state and contribute to oxidative stress.4,21 In this regard, 
our results show that, paired to the development of LVH, 
there is an increase in circulating mononuclear cell NADPH 
oxidase activity. In fact, there is a direct correlation between 
the NADPH oxidase–dependent superoxide production by 
PBMCs and LVMI. Interestingly, in a study in hypertensives 
with LVH, the reduction in LVMI by treatment with antihy-
pertensive drugs correlated with a reduction in reactive oxygen 
species produced by monocytes.27 Therefore, it may be sug-
gested that humoral factors may have an effect on the NADPH 
oxidase of circulating white cells in patients with HHD.
In this regard, we have identified serum CT-1 as a potential 
candidate. CT-1 is a prohypertrophic cytokine that is increased 
Figure 3. A, Serum cardiotrophin­1 levels in 
normotensives (NT, n=18; 133±13 fmol/mL [95% 
confidence interval {CI}, 106 to 161 fmol/mL]), 
hypertensives without left ventricular hypertrophy 
(HT−LVH, n=42; 154±9 fmol/mL [95% CI, 135 
to 173 fmol/mL]), and hypertensives with LVH 
(HT+LVH, n=80; 184±5 fmol/mL [95% CI, 174 
to 195 fmol/mL]). *P=0.001 vs NT (CI, −75.90 
to −25.93); †P=0.007 vs HT−LVH (CI, −49.92 to 
−11.10). B, Correlation of serum cardiotrophin­1 
levels and superoxide production by peripheral 
blood mononuclear cells after adjusting for age, 
sex, body mass index, and systolic blood pressure. 
Open circles indicate NT; closed circles, HT−LVH; 
and open squares, HL+LVH.
Figure 4. A, Superoxide production by peripheral blood mononuclear cells on 10­minute stimulation with human cardiotrophin­1 (hCT­1), in 
the presence or absence of Cu,Zn­SOD (enzymatic scavenger of superoxide), diphenylene iodonium (DPI, flavoprotein inhibitor), apocynin 
(inhibitor of phagocytic NADPH oxidase assembly), gp91ds­tat (inhibitor of phagocytic NADPH oxidase assembly), rotenone (inhibitor of 
mitochondrial chain), oxypurinol (inhibitor of xanthine oxidase), and L­NAME (L­NG­nitro­arginine methyl esther; inhibitor of endothelial nitric 
oxide synthase; n=6). *P<0.01 vs control. †P<0.01 vs hCT­1. B, Representative image of p47phox translocation in the absence (baseline) 
and presence of hCT­1 (5 ng/mL). C, Evaluation of the blockade of the CT­1 receptor (anti­LIFR [leukemia inhibitory factor] and anti­gp130 
antibodies) and signaling pathways (bisindolyl maleimide [BIS] ­PKC [protein kinase C] inhibitor­, wortmannin ­PI3K [phosphatidylinositide 
3­kinase]/Akt inhibitor­, and PD98059 ­MEK1/2 [MAP kinase kinase 1/2] inhibitor­) in peripheral blood mononuclear cells stimulated with 
hCT­1 (n=6). *P<0.01 vs control. †P<0.01 vs hCT­1.
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in HHD and may be a marker of LVH.27 We have now observed 
that serum CT-1 levels correlate with the NADPH oxidase–
dependent superoxide production. Our in vitro studies show that 
CT-1 can activate the NADPH oxidase of PBMCs and increase 
Nox2 expression. We propose that in addition to its local, pro-
hypertrophic effects, CT-1 may contribute to systemic oxidative 
stress. We cannot discard the effect on PBMC NADPH oxi-
dase–dependent superoxide production of other humoral fac-
tors which may be relevant in hypertension. In fact, angiotensin 
II,9 endothelin-1,9 and insulin11 activate the phagocytic NADPH 
oxidase. In addition, our in vitro results show the release of IL-6 
by PBMCs stimulated with CT-1, which is in agreement with 
Fritzenwanger et al28 who showed in monocytes from healthy 
volunteers that CT-1 induced IL-6 in a time- and concentration-
dependent manner. However, IL-6 stimulation of PBMCs did 
not result in the release of CT-1. Finally, in our study, both CT-1 
and IL-6 circulating levels correlate with the NADPH oxidase–
dependent superoxide production and LVMI. Taken together, 
our results support the idea that the systemic proinflammatory 
status may have an impact on the LV in hypertension.
We see that as a consequence of the activation of the NADPH 
oxidase caused by CT-1, PBMCs release IL-6. IL-6 is a pleio-
tropic cytokine29 expressed in a multitude of cells, especially 
in monocytes and macrophages,30 that takes part in numerous 
processes, including differentiation of white cells, migration 
and proliferation of smooth muscle cells, insulin sensitivity 
in hepatocytes, phagocyte recruitment by endothelium, and 
secretion of metalloproteinases by fibroblasts.30 Interestingly, 
a clinical study showed a correlation between higher serum 
IL-6 levels and poorer cardiac function in subjects free of car-
diovascular disease.3 In agreement with this, circulating IL-6 
levels correlate with the LVMI in asymptomatic hypertensive 
patients.31 Moreover, a recent study in mice shows that IL-6 
infusion induces cardiac hypertrophy and fibrosis, yielding a 
myocardial phenotype that resembles HHD.32
Our finding showing that CT-1–induced IL-6 secretion can 
be blocked by apocynin suggests that therapies that directly 
or indirectly inhibit the NADPH oxidase may be beneficial in 
HHD. Interestingly, the treatment of patients with HHD with 
valsartan could both reduce monocyte-derived reactive oxygen 
species and LVH.27 We have recently showed that the EXP3179 
metabolite of losartan diminished the NADPH oxidase activity 
of circulating white cells,33 which may be one of the factors 
that explain the beneficial effects of losartan, including LVH 
regression.34 It would be interesting to evaluate whether the 
effect of current medication for HHD is mediated by reduced 
systemic superoxide production by the NADPH oxidase.
One of the limitations of our study is the relatively small 
number of patients included in it. Further studies with larger 
samples are necessary to corroborate the association of the 
NADPH oxidase activity of circulating cells, cytokines, 
and cardiac structure and function, as well as to determine 
whether the phagocytic NADPH oxidase activity may be a 
marker of HHD. We are aware that other cells present in the 
cardiovascular system express the NADPH oxidase system 
as well as other pro-oxidant systems (such as the mitochon-
dria or the uncoupled nitric oxide synthase), and therefore the 
PBMC NADPH oxidase may be one of many determinants 
of oxidative stress involved in LVH. Finally, we realize that 
pharmacological treatment may be a confounding factor in 
our study because antihypertensive drugs against the renin–
angiotensin system as well as statins may inhibit the NADPH 
oxidases.35 Nevertheless, there were no significant differences 
in these treatments between the hypertensives without LVH 
(HT−LVH) and the HT+LVH groups.
Perspectives
Our findings suggest that, in addition to the important role of 
infiltrated white cells in cardiovascular pathophysiology, circu-
lating phagocytes may contribute to the development of HHD 
via an increased superoxide generation by the NADPH oxidase 
and the subsequent release of IL-6 (Figure S9). In addition to 
its local, prohypertrophic effect on the heart, CT-1 may be one 
of the factors contributing to a systemic proinflammatory and 
pro-oxidant profile in patients with HHD, via an enhanced 
NADPH oxidase activity in PBMCs. Systemic oxidative stress 
and inflammation may be relevant mechanisms and therapeu-
tic targets in HHD, thus drawing attention to the necessity of 
clinical studies to assess its state in the different stages of this 
cardiac disease.
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What Is New?
•	The systemic overactivity of the pro-oxidant phagocytic NADPH oxidase 
associates with cardiac structural and functional alterations in hyperten-
sive patients.
•	Cardiotrophin-1, a key prohypertrophic cytokine, promotes NADPH oxi-
dase activation in circulating phagocytes.
What Is Relevant?
•	The phagocytic NADPH oxidase may be a relevant novel therapeutic tar-
get in hypertensive heart disease.
Summary
In addition to the important role of infiltrated white cells in cardio-
vascular pathophysiology, circulating phagocytes may contribute 
to the progression of hypertensive heart disease via an increased 
superoxide generation by the NADPH oxidase. Cardiotrophin-1 
may play a key role in the activation of the NADPH oxidase in cir-
culating phagocytes, promoting their subsequent production of 
interleukin-6.
Novelty and Significance
